These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 2139701

  • 1. Active-specific immunotherapy for melanoma.
    Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L.
    J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
    [Abstract] [Full Text] [Related]

  • 2. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM.
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA, Rimoldi D, Liénard D, Carrel S, Lejeune F, Dietrich PY, Cerottini JC, Romero P.
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.
    Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 1):76-83. PubMed ID: 14734454
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D, Mastrangelo MJ.
    Cancer Invest; 1988 Jan 01; 6(3):337-49. PubMed ID: 3167614
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
    Doré JF, Portoukalian J, Berthier-Vergnes O, Jacubovich R, Genève J, Bailly M, Lefthériotis E, Weissbrod A, Mayer M.
    Bull Cancer; 1990 Jan 01; 77(9):881-91. PubMed ID: 2224160
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
    Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL.
    Ann Surg Oncol; 1996 Sep 01; 3(5):437-45. PubMed ID: 8876885
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.